New & Notable
Amylin could reign supreme in the next wave of obesity drugs
With investment in amylin analogs on the rise for weight management, three key candidates are inching closer to critical readouts.
— PharmaVoice
Consumer confusion fuels risky online drug purchases, survey finds
Due to widespread misunderstandings, many U.S. adults are buying drugs, especially GLP-1 products, from online, unlicensed sellers, a new survey reveals.
Wegovy linked to liver health benefits at low levels of weight loss
Wegovy may improve liver injury and scarring in adults with MASH and moderate-to-severe fibrosis, even without significant weight loss, data shows.
Pfizer wins bidding war for Metsera with $10B offer
The new proposal for the coveted obesity drug developer is more than double the size of Pfizer’s original bid and ends a squabble with Novo Nordisk that had resulted in lawsuits.
— Biopharma DiveCMMI to launch model to lower Medicaid drug spending
— Healthcare DiveNovo, Lilly cut deal with Trump to lower prices of obesity drugs
— Biopharma DiveHealthcare Strategies: A Podcast
-
A podcast for healthcare professionals seeking solutions to today's and tomorrow's top challenges. Hosted by the editors of Xtelligent Healthcare Media, this podcast series focuses on real-world use cases that are leading to tangible improvements in care quality, outcomes, and cost.
Guests from leading provider, payer, government, and other organizations share their approaches to transforming healthcare in a meaningful and lasting way.
View All Episodes
Latest News
-
Innovent, Lilly's mazdutide outdoes Novo's semaglutide in phase 3 trial
Innovent Biologics and Eli Lilly's dual GLP-1/glucagon agonist, mazdutide, beats Novo Nordisk's semaglutide in a phase 3 trial of adults with diabetes and obesity.
-
Report: Bipartisan support for patent reform to lower drug prices
Four in five Americans support changing patent laws to lower drug costs, favoring patent reform over government price controls by 15 points, says a new I-MAK report.
-
Report: Compounded GLP-1 drugs pose safety, quality risks
Compounded GLP-1 drugs pose safety and quality risks, a recent report says, adding to the growing calls for tougher regulatory enforcement.
-
CVS Rx Report: 5 latest trends influencing community pharmacy
CVS Health's 2025 Rx Report highlights key community pharmacy trends, showing how patient needs, workforce pressures and sustainable care models are shaping care.
-
AstraZeneca joins Pfizer in most-favored nation pricing program
AstraZeneca joins Pfizer in the White House's most favored nation drug pricing program, expanding TrumpRx's reach but raising questions about real-world savings.
-
GLP-1 drugs can interfere with FDG-PET-CT scans, study says
Taking GLP-1 receptor agonists can cause atypical tracer uptake patterns in the body that could be mistaken for inflammation or cancer in FDG-PET-CT scans.
Features
-
Blurring the line between GLP-1 compounders, counterfeiters
Weak regulatory oversight has allowed 503A compounding facilities to abuse customization rules, blurring the line between GLP-1 compounders and unregulated drug manufacturers.
-
Expanding clinical trial access through technology, support
Systemic barriers continue to restrict clinical trial access, but when deployed correctly, technology can provide patient–provider support and close interoperability gaps.
-
Will the FDA's green list end illegal GLP-1 compounding?
The FDA recently created a green list to regulate imported GLP-1 drug ingredients, yet experts say that weak enforcement could allow illegal compounding operations to continue.
-
Using AI to identify, expose online drug counterfeiters
Pharmaceutical companies are leveraging AI's advanced detection and enforcement tools to combat the online counterfeit drug market, protecting brand integrity and consumer safety.